Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-12-17

FDA Approved: IBANDRONATE SODIUM — Supplemental Application (Apotex Corp.)

View source ↗

Summary

The FDA approved a supplemental application for Apotex Corp. to market a generic ibandronate sodium product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • IBANDRONATE SODIUM (ibandronate sodium)

Snippet

SUPPL AP for IBANDRONATE SODIUM (IBANDRONATE SODIUM)